SAB Biotherapeutics, Inc. (SABSW) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Sioux Falls, SD, 美国. 现任CEO为 Samuel J. Reich.
SABSW 拥有 IPO日期为 2021-10-25, 63 名全职员工, 在 NASDAQ Global Market, 市值为 $238.95K.
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
